Patent intelligence · US
US 6451316
Methods for generating antigen-reactive T cells in vitro
Methods for generating antigen-reactive T cells in vitro
Patent details — US 6451316
- Jurisdiction
- US
- Status
- expired
- Grant date
- Sep 17, 2002
- Expiration
- Sep 12, 2022
- Applicant
- University of Connecticut Health Center
- Claims
- 35
- CPC classes
- A61K, A61K2039/6043, A61K2039/622, A61K40/11
Quick answer
US 6451316 (Methods for generating antigen-reactive T cells in vitro) is held by University of Connecticut Health Center. Status: expired. Granted Sep 17, 2002. Expires Sep 12, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- University of Connecticut Health Center
- Grant date
- Expiration
- Claims
- 35
- CPC classes
- A61K, A61K2039/6043, A61K2039/622, A61K40/11, A61K40/4262, A61P
More from University of Connecticut Health Center
Related pharmaceutical patents in our USPTO index.
-
US 12311017
Identification of immunologically protective neo-epitopes for the treatment of cancers
granted -
US 12251378
Long-acting local anesthetic formulation
granted -
US 12202822
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 12156879
Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy
granted -
US 12060555
MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis
granted -
US 12029787
Method for generating recombinant poxviruses
granted -
US 12018255
Compositions and methods for treating disorders of genomic imprinting
granted -
US 11952419
Reagents and methods for treating cancer and autoimmune disease
granted
Frequently asked questions
What is US patent 6451316?
US 6451316 (Methods for generating antigen-reactive T cells in vitro) is held by University of Connecticut Health Center. Status: expired. Granted Sep 17, 2002. Expires Sep 12, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6451316?
University of Connecticut Health Center is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 179 pharmaceutical patents for this assignee.
When does US 6451316 expire?
Our index shows an expiration date of Sep 12, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.